| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $287,368 | 4 | 100 |
Sells | $0 | 0 | 0 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 2 | $198,358 | 0 | $0 | $198,358 |
| Pennell Sandra | Chief Financial Officer | 1 | $50,018 | 0 | $0 | $50,018 |
| Sylvester John Richard | director | 1 | $38,992 | 0 | $0 | $38,992 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Over the last 12 months, insiders at Delcath Systems, Inc. have bought $287,368 and sold $0 worth of Delcath Systems, Inc. stock.
On average, over the past 5 years, insiders at Delcath Systems, Inc. have bought $623,362 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MICHEL GERARD J (CHIEF EXECUTIVE OFFICER) — $198,358. Pennell Sandra (Chief Financial Officer) — $50,018. Sylvester John Richard (director) — $38,992.
The last purchase of 5,533 shares for transaction amount of $50,018 was made by Pennell Sandra (Chief Financial Officer) on 2026‑03‑06.
| 2026-03-06 | Pennell Sandra | Chief Financial Officer | 5,533 0.0159% | $9.04 | $50,018 | +0.44% | ||
| 2026-03-02 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 11,200 0.0325% | $8.96 | $100,309 | +1.57% | ||
| 2025-11-21 | Sylvester John Richard | director | 4,386 0.0125% | $8.89 | $38,992 | +11.05% | ||
| 2025-11-11 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 11,500 0.0327% | $8.53 | $98,049 | +15.08% | ||
| 2024-03-19 | SALAMON STEVEN A J | director | 26,882 0.106% | $3.72 | $100,001 | +110.63% | ||
| 2024-03-19 | Aharon Gil | director | 26,882 0.106% | $3.72 | $100,001 | +110.63% | ||
| 2023-12-12 | Vukovic Vojo | Chief Medical Officer | 40,000 0.1728% | $3.00 | $120,000 | +140.73% | ||
| 2023-12-08 | MICHEL GERARD J | Chief Executive Officer | 34,000 0.1516% | $2.94 | $99,960 | +150.00% | ||
| 2023-11-17 | Rosalind Advisors, Inc. | director | 100,000 0.6437% | $2.40 | $240,410 | +175.31% | ||
| 2023-11-17 | Pennell Sandra | SVP of Finance, PFO and PAO | 30,000 0.1952% | $2.43 | $72,900 | +175.31% | ||
| 2023-11-16 | Vukovic Vojo | Chief Medical Officer | 60,000 0.3928% | $2.48 | $148,800 | +172.47% | ||
| 2023-11-16 | Hoffman David L. | See Remarks | 40,000 0.2618% | $2.48 | $99,200 | +172.47% | ||
| 2023-10-13 | Purpura John | Chief Operating Officer | 14,505 0.0944% | $3.44 | $49,897 | +44.51% | ||
| 2023-08-21 | Sylvester John Richard | director | 10,550 0.093% | $4.80 | $50,640 | -8.86% | ||
| 2023-03-29 | MICHEL GERARD J | Chief Executive Officer | 19,646 0.0001% | $4.84 | $95,087 | -19.86% | ||
| 2022-12-14 | Rosalind Advisors, Inc. | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | ||
| 2022-12-14 | SALAMON STEVEN A J | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | ||
| 2022-12-13 | MICHEL GERARD J | Chief Executive Officer | 51,725 0.4573% | $2.90 | $150,003 | +26.22% | ||
| 2022-07-20 | MICHEL GERARD J | Chief Executive Officer | 62,814 0.6782% | $3.98 | $250,000 | +7.50% | ||
| 2022-05-16 | Purpura John | Chief Operating Officer | 3,300 0.0396% | $4.61 | $15,213 | -13.01% |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 342034 0.9857% | $3.11M | 13 | 0 | <0.0001% |
| Pennell Sandra | Chief Financial Officer | 77018 0.222% | $699,323.44 | 2 | 0 | +175.31% |
| Sylvester John Richard | director | 14936 0.043% | $135,618.88 | 2 | 0 | <0.0001% |
| SALAMON STEVEN A J | director | 1121025 3.2306% | $10.18M | 14 | 0 | <0.0001% |
| Aharon Gil | director | 1069710 3.0827% | $9.71M | 3 | 0 | +23.8% |
| Rosalind Advisors, Inc. | director | 1038828 2.9937% | $9.43M | 12 | 0 | <0.0001% |
| LADD ROBERT | director | 631294 1.8193% | $5.73M | 48 | 11 | |
| Taglietti Marco | director | 220000 0.634% | $2M | 2 | 0 | |
| Philips Laura A | director | 205299 0.5916% | $1.86M | 8 | 0 | |
| HOBBS EAMONN P | President and CEO | 162000 0.4669% | $1.47M | 2 | 0 | |
| Taney Richard | Chief Executive Officer | 161000 0.464% | $1.46M | 5 | 0 | |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 160375 0.4622% | $1.46M | 2 | 10 | |
| Kandarpa Krishna | Exec. V.P., Chief Medical Off. | 150000 0.4323% | $1.36M | 0 | 1 | |
| Koplewicz Harold S | director | 148521 0.428% | $1.35M | 5 | 0 | |
| CORIGLIANO MARK | director | 141225 0.407% | $1.28M | 0 | 1 | |
| Vukovic Vojo | Chief Medical Officer | 100000 0.2882% | $908,000.00 | 2 | 0 | +156.6% |
| WATSON DOUGLAS G | director | 61369 0.1769% | $557,230.52 | 1 | 0 | |
| Miao Graham G | Exec. V.P., CFO | 54000 0.1556% | $490,320.00 | 1 | 0 | |
| Purpura John | Chief Operating Officer | 41526 0.1197% | $377,056.08 | 7 | 0 | <0.0001% |
| Hoffman David L. | See Remarks | 40000 0.1153% | $363,200.00 | 1 | 0 | +172.47% |
| LEUNG GABRIEL | director | 15847 0.0457% | $143,890.76 | 1 | 0 | |
| Rueckert William Dodge | director | 7926 0.0228% | $71,968.08 | 3 | 0 | |
| Keck Barbra | Chief Financial Officer | 7500 0.0216% | $68,100.00 | 3 | 0 | |
| Simpson Jennifer K. | President & CEO | 7500 0.0216% | $68,100.00 | 3 | 0 | |
| STOLL ROGER G PHD | director | 5901 0.017% | $53,581.08 | 5 | 0 | |
| KOLY M S /FA/ | President and CEO | 0 0% | $0 | 0 | 2 |
| Increased Positions | 63 | +46.67% | 2M | +12.22% |
| Decreased Positions | 55 | -40.74% | 3M | -17.15% |
| New Positions | 20 | New | 829,036 | New |
| Sold Out Positions | 19 | Sold Out | 2M | Sold Out |
| Total Postitions | 143 | +5.93% | 17M | -4.93% |
| Rosalind Advisors, Inc. | $32,839.00 | 9.43% | 3.3M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $17,601.00 | 5.05% | 1.77M | +51,757 | +3.01% | 2025-09-30 |
| Vanguard Group Inc | $16,491.00 | 4.74% | 1.66M | +46,693 | +2.9% | 2025-09-30 |
| Geode Capital Management, Llc | $6,842.00 | 1.97% | 687,613 | -15,558 | -2.21% | 2025-09-30 |
| Nantahala Capital Management, Llc | $6,631.00 | 1.9% | 666,435 | +666,435 | New | 2025-09-30 |
| State Street Corp | $6,181.00 | 1.78% | 621,250 | +147,357 | +31.09% | 2025-09-30 |
| Vivo Capital, Llc | $5,667.00 | 1.63% | 569,526 | 0 | 0% | 2025-09-30 |
| Divisadero Street Capital Management, Lp | $4,738.00 | 1.36% | 476,160 | +476,160 | New | 2025-09-30 |
| Citadel Advisors Llc | $4,471.00 | 1.28% | 449,315 | -353,893 | -44.06% | 2025-09-30 |
| Propel Bio Management, Llc | $4,363.00 | 1.25% | 438,509 | +212,457 | +93.99% | 2025-09-30 |